Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

calendar_today October 22, 2025 person By Randy Osborne, Bioworld domain electra-therapeutics

SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced that ELA026 has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation (BTD)…

open_in_new Read original post

Discovery

Learnings

Guidance

Toolbox

Alignment

API Evangelist LLC

Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)